Client: Helmi, christien (01010016669)

Patient Name: Sasha

Species: Canine

Breed: Golden Retriever

Gender: Female Weight: 27.00 kgs

Age: 7 Years


Doctor: Nadia Essam

Dr Paws Animal Hospital New Cairo - First Settlement 01008886446 - 01117873666

Test	Results	Reference Interva	LOW	NORMAL	HIGH
VetAutorea	ad (August 11, 202	21 12:13 PM)			8/11/21 11:58 AM
нст	55.1 %	37.0 - 55.0 HIGH			56.6 %
HGB	# 15.6 g/dL	12.0 - 18.0			# 13.5 g/dL
MCHC	# 28.3 g/dL	30.0 - 36.9 LOW			g/dL
WBC	# 5.10 K/µL	6.00 - 16.90 LOW		The second second	Κ/μL
GRANS	# 2.60 K/µL	3.30 - 12.00 LOW			K/μL
GRANS	# 51.0 %				%
/M	# 2.5 x10^9/L	1.1 - 6.3			x10^9/L
6L/M	# 49 %				, %
LT	# 264 K/µL	175 - 500	Section Desired		K/μL
IRBC	Likely				^

Buffy Coat (1) Granulocytes have not separated cleanly from the lymph/mono layer. Confirm results with a blood smear.

Buffy Coat (4) Buffy coat layers inconsistent due to clumped platelets, expired tube or stain on tube exterior. Remove tube, carefully clean exterior, and retest. If situation persists, obtain a fresh sample and retest,



Client: Helmi, christien (01010016669)

Patient Name: Sasha Species: Canine

Breed: Golden Retriever

Gender: Female Weight: 27.00 kgs Age: 7 Years

Doctor: Nadia Essam

Dr Paws Animal Hospital New Cairo - First Settlement 01008886446 - 01117873666

Test	Results	Reference Inte	erval LOW	NORMAL	HIGH	
Catalyst On	ne (August 11, 202	21 12:15 PM)				
FRU	284 µmol/L	177 - 314	N-			
SDMA	56 μg/dL	0 - 14 H	IIGH			

Fructosamine concentration is a marker of mean blood glucose concentrations during the preceding 2 to 3 weeks. The higher the average blood glucose concentration is over this time, the higher the fructosamine concentration. The chart below can be used to help determine effectiveness of therapy in diabetic patients already receiving therapy. Results should be interpreted in conjunction with clinical signs and other laboratory results. For dogs with inadequate control, consider a serial blood glucose curve, causes of insulin resistance and possibility of Somogyi phenomenon before increasing the insulin dose.

Fructosamine (µmol/L)

Glycemic control in diabetic patients receiving therapy

300 to 400 Good 400 to 450 Fair >450 Poor

<300 Possibilities include:

Good control

Prolonged hypoglycemia

SDMA:

IF BOTH SDMA AND CREATININE ARE WELL WITHIN THE REFERENCE INTERVAL, then kidney function is likely good. Evaluate a complete urinalysis and confirm there is no other evidence of kidney disease.

IF SDMA IS INCREASED BUT CREATININE IS WITHIN THE REFERENCE INTERVAL. Catalyst SDMA Test is a more reliable indicator of kidney function than creatinine because SDMA detects declining kidney function earlier and is not impacted by muscle mass. Creatinine can miss early function loss and be falsely decreased in patients with poor muscle mass. SDMA increases in acute and active injury as well as chronic kidney disease. A complete urinalysis should be performed to evaluate for inappropriate specific gravity, proteinuria and other evidence of kidney disease. For information on recommended actions visit: idexx.com/SDMAalgorithm (U.S.), idexx.ca/AlgorithmSDMA (Canada) or idexx.eu/SDMAalgorithm (EU).

IF SDMA IS WITHIN THE REFERENCE INTERVAL AND CREATININE IS INCREASED. This combination of results is uncommon. SDMA and creatinine can both be affected by biologic and assay variability resulting in fluctuations around the upper end of the reference interval; this can be seen with well-managed stable CKD and results will likely align as disease progresses. Creatinine can exceed the reference interval in muscular dogs with normal kidney function. Creatinine can be artifactually increased postprandially. If kidney disease is still suspected, a complete urinalysis should be performed on all patients to evaluate for inappropriate specific gravity, proteinuria or other evidence of kidney disease.

IF BOTH SDMA AND CREATININE ARE INCREASED, then kidney disease is probable and action should be taken. A complete urinalysis should be performed to evaluate for inappropriate urine specific gravity, proteinuria or other evidence of kidney disease. For information on recommended actions visit: idexx.com/SDMAalgorithm (U.S.), idexx.ca/AlgorithmSDMA (Canada) or idexx.eu/SDMAalgorithm (EU).



Biochemical Inspection Report

Name:

Sasha

Serum

Sex: Female

Age: 7

Years

ID:

Bed No.:

Sample Type:

Department:

Surgery

Patient Area:

In-patient

Clinical Diagnosis:

LOT:

34210-32.2-0142-0223-20-201280-196

Abnormal Sample: Hemolysis

Item	Result	Indicator	Ranges	Unit	Item	Result	Indicator	Ranges	Unit
ALT	56		10-118	U/L	CHOL	≥542		124-271	mg/dL
AST	279	1	8.9-48.5	U/L	HDL-C	≥115		44.6-54.6	mg/dL
TBIL	0.55		0-0.6	mg/dL	LDL-C	289.80	↑	0-120	mg/dL
DPIL	0.35		0-0.35	mg/dL					
IBIL	0.20		0-1	mg/dL					
TP	7.86		5.4-8.2	g/dL					
ALB	2.86		2.5-4.4	g/dL					
GLO	5.00	†	2-4	g/dL					
A/G	0.60/1	1	1.2-2.4/1						
JREA	≥214		37-92.4	mg/dL					
CRE	5.99	↑	0.3-1.5	mg/dL					
GLU	121		70-143	mg/dL					
TG	288	1	9-80	mg/dL					

Submit Datetime: ۲.۲۱-.۸-۱۱ ۲۳:۳۹

Analysis Datetime:

Y.Y1_.A_11 1A: 9

Print Datetime:

2021-08-11 12:32

Submitter:

Operator:

Reviewer:

Nadia Essam

The result is only responsible for this sample

Remark:

Biochemical Inspection Report

Name: Sample Type:

Serum

Sex: Male

Department:

Age:

Surgery

Years

ID:

Patient Area:

UIUIUUIO Bed No.:

In-patient

Clinical Diagnosis:

LOT:

34210-32.2-0142-0223-17-201281-93

Abnormal Sample: Hemolysis

Item	Result		Tientolysis		
	Result	Indicator	Ranges		
K+	5.45			Unit	
Na+	142		3.7-5.8	mmol/L	
Cl-	105		138-160	mmol/L	
CO2		↓	106-120	mmol/L	
	11.00		12-27		
Ca2+	11.46		8.6-11.8	mmol/L	
Mg2+	2.81	^		mg/dL	
Р			0.74-0.99	mg/dL	
	≥10.8		2.9-6.6	mg/dL	
				0	

Submit Datetime:

Submitter:

Remark:

Analysis Datetime:

Operator:

7.71-1.11 11:54

Print Datetime:

2021-08-11 13:01

Reviewer:

The result is only responsible for this sample